[{"id":"0092a625-24d4-44f5-8f0f-2bc0a8d303ac","acronym":"","url":"https://clinicaltrials.gov/study/NCT04629729","created_at":"2021-01-19T20:36:15.323Z","updated_at":"2024-07-02T16:35:30.577Z","phase":"Phase 1","brief_title":"FT819 in Subjects With B-cell Malignancies","source_id_and_acronym":"NCT04629729","lead_sponsor":"Fate Therapeutics","biomarkers":" CD19 • IL2","pipe":" | ","alterations":" CD19 expression","tags":["CD19 • IL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD19 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • bendamustine • fludarabine IV • FT819"],"overall_status":"Recruiting","enrollment":" Enrollment 396","initiation":"Initiation: 07/26/2021","start_date":" 07/26/2021","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2039","study_completion_date":" 09/30/2039","last_update_posted":"2023-11-02"}]